The times, they are a-changin’ — and in healthcare you’re either a “believer” in the next wave of innovation or a “non-believer” too firmly entrenched in the traditional ways of doing business, according to a new report from PwC.
In embracing a “$1 trillion opportunity” for reinvention, the future is for the believers, PwC pharmaceutical and life sciences lead Philip Sclafani said. And in terms of pharma’s role in that healthcare transformation, the answer lies in R&D efficiency and business diversification.
With a U.S. healthcare system that carries more than $5 trillion in spending each year, PwC’s report said that $1 trillion of that spending is expected to shift “away from fragmented, infrastructure-heavy models and toward empowered ‘super consumers’ and a digital-first, proactive and personalized system of care.”
For drugmakers, a…